BD-p-tau217% is the proportion of brain-derived plasma tau phosphorylated at threonine 217. It was tested in autopsy (323), PET (242) and clinical (1,386) cohorts from one Pittsburgh memory clinic. It separated low from severe neuropathological change with an AUC of 0.93, against 0.90 for standard p-tau217. For amyloid PET it had 92% sensitivity and 88% specificity, against 79% and 82% for p-tau217. High levels predicted clinical progression, with hazard ratios of 3.21 in clinically unimpaired people and 3.65 in mild cognitive impairment. Limits include a single centre, a 91.5% non-Hispanic White clinical cohort, and no significant AUC gain for unimpaired progressors.
Why it is interesting: Standard p-tau217 partly comes from tissues outside the brain, which may cloud blood-based diagnosis in older people with other illnesses. Here accuracy stayed at AUC 0.84 to 0.88 among those with comorbidities.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.